A method for the identification of a composition useful in the treatment of an overweight or obese person to reduce the person's body mass index is provided which comprises obtaining an extract of an ethnobotanical plant, and evaluating the activity of the extract in an assay selected from the group consisting of a lipolysis assay, an assay that measures the amount of glycerol introduced by a cell into a suspension medium of the cell, an adipocyte differentiation assay, an assay that measures the level of the enzyme glycerol-3-phosphate dehydrogenase, an assay that measures the inhibition of differentiation of preadipocytes to adipocytes, an assay that measures the accumulation of lipid in an adipocyte, an assay that measures the de-differentiation of adipocytes into preadipocytes, and combinations thereof. Sclareol and sclareol-like compounds and sclareolide and sclareolide-like compounds are identified as useful in the treatment of overweight and obese conditions and disorders and conditions associated with adipose tissue abnormalities. These compounds can be formulated for oral administration.

Phytomyco Research Corporation

Identification of compositions, compositions, and methods of treatment of obesity and overweight conditions

Methods and devices for delivering electrical stimulation to the sympathetic nervous system in response to the onset of eating. In some methods, swallowing is detected which then initiates a dose of stimulation which can vary in intensity, frequency, or both over the dose length. In some methods, the dose length is between about one quarter hour and one hour. The dose frequency may increase, hold steady, then decrease over the dose duration so as to mimic the response of the gut stretch and nutrient receptors to receiving food. The dose can drive biomarkers indicative of eating, for example glucagon, glucose, FFA or glycerol to at least about half of their normal post eating levels and then stop so as to retain stimulation effectiveness for subsequent doses and to prolong battery life.

Advanced Neuromodulation Systems, Inc.

Esophageal activity modulated obesity therapy

The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.

Liu; Shuang

Guo; Cheng

Albany Molecular Research, Inc.

SGLT-2 inhibitors, methods of making them, and uses thereof

Substituted heterocyclic derivatives are provided which have the structure ##STR00001## wherein Z.sup.1 is (CH.sub.2).sub.q or C.dbd.O; Z.sup.2 is (CH.sub.2).sub.p or C.dbd.O; D is --CH.dbd. or C.dbd.O or (CH.sub.2).sub.m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; X is CH or N; X.sub.2 is C, N, O or S; X.sub.3 is C, N, O or S; X.sub.4 is C, N, O or S; X.sub.5 is C, N, O or S; X.sub.6 is C, N, O or S; provided that at least one of X.sub.2, X.sub.3, X.sub.4, X.sub.5 and X.sub.6 is N; and at least one of X.sub.2, X.sub.3, X.sub.4, X.sub.5 and X.sub.6 is C; A, B, R.sup.1, R.sup.2, R.sup.2a, R.sup.2b, R.sup.4, R.sup.3, E, Z and Y are as defined herein. In addition, a method is provided for treating diabetes, Type 2 diabetes, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, or atherosclerosis, wherein the substituted heterocyclic derivatives are administered in a therapeutically effective amount to a patient.

glycerol/rasvumus

Identification of compositions, compositions, and methods of treatment of obesity and overweight conditions

Esophageal activity modulated obesity therapy

SGLT-2 inhibitors, methods of making them, and uses thereof

Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus